OLMA Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -0.26%, SMA50 -7.2%, SMA200 84.4%). The stock’s 14-day RSI is 48.21 (neutral), while the ATR of 1.59 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -32.73% below its high and over 752.8% above its low. Average 10-day trading volume of 1.44 million shares is in line with the 3-month average of 1.53 million, indicating normal recent market interest.

Olema Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.54. This means the shares are trading above this model’s fair value.

Olema Pharmaceuticals, Inc. has 68.63 million shares outstanding. The public float is 39.65 million shares, elevated short interest at 12.28% of float. This equals 7.64 million shares. The short ratio is 16.64 days. Institutional investors hold 108.32% of the float. Insiders own 3.31%. Bain Capital Life Sciences Investors, LLC holds 7.80 million shares, Cormorant Asset Management, LP has 3.27 million shares and LAMPERT MARK N has 2.91 million shares. Over the past six months, insider transactions show net selling. They sold 440.94 thousand shares across 15 transactions.

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) closed at $10.31 USD, losing -$0.37 (-3.46%) from the previous close of $10.68. The stock is currently mid-range between its 52-week high and low $3.89 and $36.26. With a market capitalization of about $900.55 million, Olema Pharmaceuticals, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.00). Key stats such as the average daily volume over the past year has been around 1.51 million shares, in line with its 52-week average. Headquartered in San Francisco, CA, Olema Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sean Bohen, the company employs approximately 96 people and listed since November 19, 2020. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers.

Olema Pharmaceuticals, Inc. generated EPS of -$1.81 over the past year. Five-year average earnings growth is -83.0%. Wall Street analysts project EPS growth of -3.11% annually over the next five years. The latest quarter delivered EPS of -$0.52. The next quarter is forecast at -$0.51. Next year's EPS is expected at -$1.24. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 16 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $62.00 to $20.00. The high target offers 501.36% upside. The low target suggests 93.99% downside. The mean target is $38.55. This offers 273.91% upside. Olema Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by 0.0%. The prior quarter beat by -1.96%. Over the last six quarters, Apple has recorded several small beats. These include -19.05% in March 18, 2025.

Our AI price prediction model suggests that Olema Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -9.12%, with price expected at $9.37 by June 19, 2026, within a range of $8.64 to $10.04 3-Month Outlook: Projected fall of -85.55%, reaching $1.49 by September 03, 2026, with a range of $0.91 to $1.94. 1-Year Outlook: Projected gain of 66.73%, with price at $17.19 by June 04, 2027, within a range of $16.71 to $17.85.

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) shares are flat 6.88% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Olema Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -5.57. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $30.67, suggesting 197.48% upside. Our AI forecast model points to short-term weakness (-9.12% over two weeks), a medium-term fall (-85.55% over three months), and a longer-term gain (66.73% over one year), with expected trading ranges indicating moderate volatility.

Olema Pharmaceuticals, Inc. trades at a P/E ratio of -5.57, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.15 suggesting the stock is closer to book value. The P/FCF stands at -5.89, also above market averages.